Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
5.43 AUD | -3.89% | -15.63% | -51.61% |
May. 15 | BMO Capital Adjusts Price Target on Arcadium Lithium to $5.50 From $6, Maintains Market Perform Rating | MT |
May. 10 | Arcadium Lithium Applies to Cease to be a Reporting Issuer in Canada | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- The company is in a robust financial situation considering its net cash and margin position.
- The company's share price in relation to its net book value makes it look relatively cheap.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- With an enterprise value anticipated at 3.43 times the sales for the current fiscal year, the company turns out to be overvalued.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Specialty Chemicals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-51.61% | 3.89B | - | ||
+21.77% | 68.97B | A- | ||
-3.91% | 47.18B | A- | ||
+24.43% | 44.73B | B+ | ||
+32.56% | 28.22B | A- | ||
+7.93% | 19.22B | C+ | ||
+11.75% | 16.75B | B+ | ||
-7.23% | 15.74B | B+ | ||
-20.33% | 16.1B | A- | ||
-25.09% | 12.72B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- ALTM Stock
- LTM Stock
- Ratings Arcadium Lithium plc